Abstract: Described herein is an oral sampling device, as well as methods of making and using the oral sampling device. The oral sampling device is configured to be placed inside of a human mouth to capture an analyte(s) found in bodily fluid, such as saliva, produced within the mouth. An example oral sampling device includes a body, at least a portion of which is sized to fit inside of a mouth of a human, has an outer surface, and a recess(es) defined in the outer surface to capture the analyte(s) therein. In some examples, a material of the body within the recess was subjected to a surface treatment to promote the capture of the analyte(s). In some examples, the oral sampling device includes a flavored substance disposed on at least the portion of the body that is to be received inside of a human mouth.

Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.

Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.

Abstract: A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium for receiving an indication of damage to a building from a sensor network associated with the building, where the sensor network is responsive to damage to the building. Determining a location and an extent of the damage to the building based on the indication of damage. Automatically coordinating a repair for the damage in response to determining the location and the extent of the damage.

Abstract: Provided are embodiments of para-substituted 1,1-dialkyl-4-phenylpiperazin-1-ium iodides advantageous for modulating inflammation that have been synthesized and their electrophysiology activities for ?9, ?9?10, and ?7 nAChRs compared. The para position contained alkyl or aryl amides, or heterocyclic isosteres for the amide, and the alkyl groups were varied at the ammonium piperazine nitrogen to see if compensatory changes in size at this position of the molecule impacted function. The compounds were characterized with two-electrode voltage-clamp measurements on Xenopus oocytes expressing nAChRs. General, the compounds were more potent for ?9-containing receptors than for ?7, and the majority were either full or strong partial agonists for ?9-containing nAChR.

Abstract: Systems and methods can use subscription and identity authentication management to remove paywalls from websites. Login information for access to an application can be received from a user. The application can verify that the login information is associated with a subscriber account associated with a subscriber to the application. Instructions can be received to access a provider site from the user through the application. The application can determine that the provider site is associated with the subscriber account and the user; and then determine access credentials to the provider site based on a predetermined access scheme associated with the provider site. The access credentials can be injected into a paywall associated with the provider site.

Abstract: A method for accessing customer data includes receiving an access request requesting access to customer data stored on a storage abstraction. The access request includes a justification that specifies a purpose/reason for requesting access to the customer data. The method also includes validating the justification, and after validating the justification, transmitting the justification to an external key management service associated with a customer of the customer data. The external key management service is configured to grant or deny access to the customer data based on the justification. The method also includes receiving an approved access token from the external key management service when the external key management service grants access to the customer data and accessing the customer data stored on the storage abstraction using the approved access token received from the external key management service.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.

Abstract: Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.

Abstract: Vehicle occupant anomaly detection is provided. A system can receive sensor data from sensors associated with a vehicle, the sensors including an imaging sensor and the sensor data including 3D point representations of a vehicle occupant. The system can extract a time-series features of the vehicle occupant from the 3D point representations. The system can execute a machine learning model using the time-series features to determine at least one condition of the vehicle occupant. The system can, responsive to the condition, generate an instruction to cause the vehicle to perform a navigational action.

Abstract: Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

Abstract: Fluidic devices and methods for autonomous droplet generation and methods for droplet manipulation are described. In an embodiment, the fluidic device comprises a substrate defining: an inlet reservoir shaped to receive and to carry a carrier liquid; a converging region in fluidic communication with the inlet reservoir and shaped to receive a liquid sample; a constriction adjacent to and in fluidic communication with the converging region, wherein the constriction defines a pathway configured to allow passage of fluid therethrough; a diverging region in fluidic communication with and downstream of the constriction; and an outlet reservoir in fluidic communication with the diverging region, wherein the fluidic device does not comprise a portion covering the outlet reservoir opposite the substrate.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: Antimicrobial polymer composite materials are disclosed that are suitable for making oral devices used in dental applications, such as denture bases. Acrylic resin composite materials comprising antimicrobial polymers and antimicrobial fillers provide reduction in common oral microorganisms after long-term aging, with reduced release rate of antimicrobial agents from the composite material. Antimicrobial polymers are prepared from compositions comprising acrylate and/or methacrylate monomers and polymerizable quaternary ammonium silicon-containing compounds.

Abstract: Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

Abstract: A wearable posture monitoring device is provided. The device includes a first posture sensor to measure a first bend parameter associated with shoulders of a user and a second posture sensor to measure a second bend parameter associated with vertebral column of the user. The device includes a control unit operatively coupled to the first posture sensor and the second posture sensor and is configured to compare the first bend parameter with a first predefined reference value and the second bend parameter with a second predefined reference value to detect an improper bend in one or more of the shoulders and vertebral column of the user. The control unit is further configured to display a visual indication, on a display interface associated with the posture monitoring device, to indicate the detected improper bend of one or more of the shoulders and vertebral column of the user.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.